TACSTD2 and breast carcinoma: The effect of TrMab-6 (mouse IgG2b) in the ADCC and CDC activity in TROP2-expressing cells, such as CHO/TROP2 (16) or MCF7, MDA-MB-231, and MDA-MB-468 breast cancer cell lines, was analyzed.